The reported mortality of the syndrome ranges between 10% and 40%. Liver damage secondary to eosinophilic infiltration is the most important cause of mortality. There are no consensus guidelines for the management of patients with DRESS syndrome. The most important steps for a proper management include the recognition of the syndrome and immediate discontinuation of the offending drug. The French Society of Dermatology recommends the use of systemic corticosteroids (prednisone 1 mg/kg/day) and intravenous immunoglobulin (2 gr/kg) for five days especially in patients with life threatening internal organ involvement, such as in renal or respiratory failure . Pulse methyl prednisolone treatment was also reportedly administered in a pediatric case of DRESS syndrome secondary to anticonvulsant use . Gancyclovir has been suggested in patients with severe signs and the confirmation of a major viral reactivation of HHV-6 .